Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip, Nasser Khaled Altorki, Caicun Zhou et al. · The Lancet · 2021
Cited by 1,486 works. doi:10.1016/s0140-6736(21)02098-5
Authors
- Enriqueta Felip
- Nasser Khaled Altorki
- Caicun Zhou
- Tibor Csőszi
- Ihor O. Vynnychenko
- Olexandr Goloborodko
- Alexander Valerievich Luft
- Andrey L. Akopov
- Alex Martínez‐Martí
- Hirotsugu Kenmotsu
- Yuh‐Min Chen
- Antonio Chella
- Shunichi Sugawara
- David Voong
- Fan Hong Wu
- Jing Yi
- Yu Lin Deng
- Mark L. McCleland
- Elizabeth Bennett
- Barbara Jennifer Gitlitz
References
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up